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Background: Atopic dermatitis, a chronic recurrent disease, 
is frequently encountered in clinical practice. In the last 30 
years, the prevalence of atopic dermatitis has rapidly 
increased due to industrialization. Therefore, there have 
been attempts in recent years to find new ways of treating and 
preventing atopic dermatitis. Objective: In this double-blind, 
randomized, placebo-controlled study, a combination of 
Bifidobacterium bifidum, Lactobacillus acidophilus, Lacto-
bacillus casei, and Lactobacillus salivarius strains were 
evaluated in the treatment of atopic dermatitis in pediatric 
patients. Methods: Forty pediatric patients (23 males and 17 
females) aged 1∼13 years were enrolled. One eligible 
individual who was approached declined to participate. The 
probiotic group was administered a probiotic complex 
containing  B. bifidum,  L. acidophilus,  L. casei, and L. 
salivarius for 8 weeks. The placebo group, on the other hand, 
was administered skim milk powder and dextrose. All of the 
parameters including serum cytokines, eosinophil cationic 
protein), SCORing Atopic Dermatitis (SCORAD) index, and 
total serum immunoglobulin E (IgE) were measured in both 
the probiotic group and the placebo group at the end of 8 
weeks. Results: Probiotic intervention in pediatric atopic 
dermatitis patients effectively reduced the SCORAD index 
and serum cytokines interleukin (IL)-5, IL-6, interferon (IFN)-
γ, and total serum IgE levels, but did not reduce levels of 
serum cytokines IL-2, IL-4, IL-10, ECP, or tumor necrosis 
factor-α  (TNF-α) compared to the placebo group. 
Conclusion: Our study found probiotics to be effective in 
reducing atopic dermatitis patients' SCORAD index, serum 
IL-5, IL-6, IFN-γ, and total serum IgE levels but not effective 
in reducing serum IL-2, IL-4, IL-10, ECP, or TNF-α levels. 
(Ann Dermatol 24(2) 189∼193, 2012)
-Keywords-
Atopic dermatitis, Cytokines, Probiotics, SCORAD index
INTRODUCTION
Atopic dermatitis (AD) is a common infant or early 
childhood disease for which genetic factors may create a 
disposition and is triggered by a variety of antigens. AD is 
characterized by chronic or relapsing inflammatory der-
matitis
1. Atopy is described as “a personal or familial 
tendency to produce IgE antibodies in response to low 
doses of allergens, usually proteins, and to develop typical 
symptoms such as asthma, rhinoconjunctivitis, or AD
2.” 
The prevalence of AD has increased in with industriali-
zation
3. Thus, new approaches have attracted interest in 
the treatment of AD. 
While probiotic means “for life,” allergic diseases (AD, 
allergic rhinitis, asthma, etc.) have been demonstrated in 
the treatment of many systemic diseases
4. In this study, we 
have examined the clinical and anti-inflammatory effects 
of probiotic supplementation in pediatric patients with 
AD.
MATERIALS AND METHODS
Forty pediatric patients (23 males and 17 females) aged 1
∼13 years participated in the study between October Y Yeşilova, et al
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Table 1. Changes in the levels of serum cytokines, SCORAD index, and total serum IgE levels and comparisons before and after 
probiotic and placebo administration
Parameters
BT mean±SD 
of probiotic
group (n=20)
AT mean±SD
of probiotic
group (n=20)
BT mean±SD
of placebo
group (n=20)
AT mean±SD
of placebo
group (n=20)
p-
value*
IL-2 (pg/ml) 42.21±20.77 29.83±14.05 32.25±15.59 28.46±21.36 0.023
IL-4 (pg/ml) 31.34±27.96 25.12±15.16 19.51±17.75 19.51±17.75 0.67
IL-5 (pg/ml) 53.60±54.90 35.97±28.57 28.47±29.90 30.53±27.25 0.0012
IL-6 (pg/ml) 21.40±64.90  5.26±4.99  4.00±5.18  6.56±11.61 0.0016
IL-10 (pg/ml) 18.21±10.41 17.15±8.51 14.30±9.54 18.02±10.95 0.013
TNF-α (pg/ml) 32.90±24.06 29.55±19.06 22.95±22.58 22.81±22.26 0.437
IFN-γ (pg/ml) 16.52±15.37 15.40±16.20 13.95±9.48 27.45±28.53 0.0011
ECP (ng/ml) 20.42±20.29 18.24±20.22 19.72±21.11 21.87±21.45 0.021
SCORAD index  35.4±13.4  12.4±7.2  28.1±6.1  15.3±5.1 0.0015
Serum total IgE (IU/ml)   427±500 281.9±405 337.3±298 347.7±271.3 0.0035
SCORAD: SCORing Atoptic Dermatitis, BT: before treatment, SD: standard deviation, AT: after treatment, IL-2: interleukin-2, IL-4: 
interleukin-4, IL-5: interleukin-5, IL-6: interleukin-6, IL-10: interleukin-10, TNF-α: tumor necrosis factor-α, IFN-γ: interferon-γ, ECP: 
eosinophil cationic protein, IgE: immunoglobulin E. *Statistical used paired t-test for testing. p values＜0.05 were considered statistically 
significant.  
2007 and April 2008. All children met the diagnostic 
criteria for AD as defined by Hanifin and Rajka
5. The 
inclusion criteria were: a moderate to severe Scoring 
Atopic Dermatitis (SCORAD) index score
6,7; being 1∼13 
years of age; absence of any other disease; having used no 
medication including antihistamines and corticosteroids 
for fourteen days prior to the study; and absence of 
gastrointestinal malabsorption.
Patients were referred to a nurse who was involved in the 
study to receive either probiotics or placebo. The nurse 
randomized each patient to two different treatment groups 
using the closed-envelope method. The authors had no 
role in the treatment decision and were blinded to the 
treatment groups. In this randomized double-blind, 
placebo-controlled study, patients were assigned to one of 
two groups, probiotics (Group 1) or placebo (Group 2). 
Group 1 (n=20) received two bags containing 2×10
9 of 
four types of probiotic bacteria (Bifidobacterium bifidum, 
Lactobacillus acidophilus, Lactobacillus casei, and Lacto-
bacillus salivarius) made by a commercially available 
supplementation (proBiotik
Ⓡ pur, Ella Farma, Münster, 
Germany), while those in Group 2 (n=20) received skim 
milk powder (Dairy Inc., Enka Milk Joint Stock Company, 
Turkey) and dextrose (Havana Chemistry, Pharmaceutical 
Medical Limited Company, Istanbul, Turkey) daily for a 
total of eight weeks. 
Blood samples collected at baseline and ten weeks later 
were followed by storing plasma frozen at −80
oC until all 
cytokine analyses were performed. Total immunoglobulin 
E (IgE) levels were analyzed using total and 3gAllergy
TM 
assays (Immulite 2,000 Immunoassay System, Siemens 
Healthcare Diagnostics, Siemens Healthcare Diagnostics 
Inc., Deerfield, IL, USA), following the manufacturer’s 
instructions. Eosinophil cationic protein (ECP) and 
cytokine levels were determined using enzyme-linked 
immunosorbent assay (BioSource International, Inc., Ca-
marillo, CA, USA) using a Triturus® System (Grifols Inter-
national S.A., manufactured by Grifols-Quest Inc.). 
The study protocol followed the Declaration of Helsinki 
and included written consent by the parents or guardians 
of the participating patients. The study was approved by 
the Drug Research Ethics Committee and was supported 
by the Scientific Research Projects.
Statistical analysis 
All analyses were conducted using SPSS 11.5 statistical 
program (SPSS Inc., Chicago, IL, USA). A ratio test was 
applied to compare the proportion of patients in groups by 
age and sex. Pre- and post-treatment differences of serum 
cytokines, total IgE levels, ECP, and changes in SCORAD 
indices were compared using a paired t-test. p-values
＜0.01 were considered statistically significant. 
RESULTS
One female patient in the placebo group failed to attend 
her follow-up visits resulting in withdrawal from the study. 
Comprising 58.9% of the patients, 23 males (aged 1∼12 
years, mean [standard deviation, SD] 7.6±3) and 16 
females (aged 1∼13 years, mean [SD] 9.3±3.2) com-
pleted the study. 
The SCORAD index changed from 35.4±13.4 to 
12.4±7.2 and from 28.1±6.1 to 15.3±5.1 in the pro-
biotic and placebo groups, respectively. The post- treat-
ment decrease in the SCORAD index in the probiotic 
group was greater than the decrease in the placebo group, The Effect of Probiotics in Atopic Dermatitis
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Fig. 1. Changes in the levels of serum cytokines, SCORAD index,
and total serum IgE and comparisons before and after probiotic
and placebo administration. SCORAD: SCORing Atoptic Derma-
titis, IgE: immunoglobulin E, IL-2: interleukin-2, IL-4: inter-
leukin-4, IL-5: interleukin-5, IL-6: interleukin-6, IL-10: inter-
leukin-10, TNF-α: tumor necrosis factor-α, IFN-γ: interferon-
γ, ECP: eosinophil cationic protein.
a difference that was statistically significant (p=0.0015; 
Table 1, Fig. 1).
As seen in Fig. 1, there was a decrease in the serum 
interleukin (IL)-5, IL-6 and interferon (IFN)-γ levels of the 
probiotic group after treatment. The difference between 
the post-treatment decreases in cytokines IL-5 (p=0.0012) 
and IL-6 (p=0.0016) and IFN-γ (p=0.0011) was statis-
tically significant compared to the difference in decreases 
of these cytokines in the placebo group. The difference 
between the rates of post-treatment decreases in the serum 
levels of IL-2 (p=0.023), IL-4 (p=0.67), IL-10 (p=0.013), 
ECP (p=0.021), and tumor necrosis factor-α (TNF-α; 
p=0.437) and the rates of post-treatment decrease of these 
cytokines in the placebo group did not have statistical 
significance. 
The serum total IgE level decreased from 427±500 IU/ml 
to 281.9±405 IU/ml in the probiotic group. In the 
placebo group, the serum total IgE increased from 337.3 
±298 IU/ml to 347.7±271.3 IU/ml. The difference 
between the post-treatment serum IgE levels of the 
probiotic group and those of the placebo group was 
statistically significant (p=0.0035). 
DISCUSSION 
There is a growing interest in using probiotic supplements 
not only by consumers for its health-promoting effects on 
a daily basis but also by health care professionals for its 
efficacy as a supplement and therapeutic product to treat a 
variety of medical conditions
8. Probiotics affect allergic 
conditions on a number of levels. In the intestinal system, 
they inhibit the epithelial and mucosal adherence of 
pathogens and prevent their invasion through the epi-
thelium
9. Probiotics compete with pathogens for limited 
loci by their ability to adhere to intestinal epithelium and 
mucus. They also inhibit the proliferation of pathogens by 
consuming the nutrients in the intestine. Furthermore, the 
antibacterial potential of certain probiotic strains involves 
secretion of hydrogen peroxide, organic acids, and bacte-
riocins that inhibit the growth of pathogens. Hydrolytic 
enzymes contribute to the increase of free fatty acids, 
short chain fatty acids, lactic acid, propionic acid, and 
butyric acid in the intestinal lumen, thus setting up an 
appropriate pH. Probiotics alter mucosal immunity consi-
derably. This involves an increase in antibody production 
and activities of phagocytes and natural killer cells, 
modulation of the nuclear factor-κB pathway, and induc-
tion of T-cell apoptosis
10. In addition, probiotics have 
been shown to modify the structure of potential allergens 
that cause allergic diseases and alleviate their immuno-
genicity
11.
Our results demonstrated an improved SCORAD index in 
both groups, but with higher levels in the probiotic group 
(65%) than in the placebo group (46%). In the probiotic 
group, a greater decrease of SCORAD index scores was 
shown after treatment in patients with high SCORAD 
index scores. However, this difference did not reach a 
statistically significant level (p=0.0015). SCORAD index 
of AD patients were evaluated before and after an 
eight-week intervention using a combination of the pro-
biotics Lactobacillus paracasei Lpc-37, Lactobacillus acid-
ophilus 74-2, and Bifidobacterium animalis subsp. lactis 
DGCC 420. It decreased by 15.5% in the probiotic group, 
while the decrease was only 8% in the placebo group
12. 
In nine of thirteen randomized controlled trials studying 
the effectiveness of probiotics in the treatment or pre-
vention of AD in children, the SCORAD index changed 
after one- or two-month probiotic administration
13. There 
are other studies on the probiotic intervention indicating 
favorable results in the SCORAD index of AD pa-
tients
14-19.
The serum total IgE level decreased from 427±500 IU/ml 
to 281.9±405 IU/ml in the probiotic group. In the 
placebo group, the serum total IgE increased from 
337.3±298 IU/ml to 347.7±271.3 IU/ml. A significant 
difference was found between the probiotic and placebo 
groups regarding total IgE levels (p=0.0035).
Our study showed probiotics to be effective in reducing 
AD patients’ serum IL-5, IL-6, and IFN-γ  levels. A Y Yeşilova, et al
192 Ann Dermatol
double-blind, placebo-controlled study, however, found 
no clinical or immunological effects of probiotics of the 
Lactobacillus strain in serum IL-4, IL-5, and IFN-γ levels 
in infants with AD compared with the placebo group after 
three months of treatment
20. Another double-blind, 
placebo-controlled study of 230 infants with atopic 
eczema/dermatitis syndrome showed no difference in 
clinical signs and serum IgE levels for the Lactobacillus 
GG-administered group and the placebo group
21. Other 
clinical studies did not report any difference in cytokine 
levels after treatment with probiotics
13,22.
As a result, our study found probiotics effective in 
reducing AD patients’ SCORAD index, serum IL-5, IL-6, 
IFN-γ, and total serum IgE levels but not effective in 
reducing serum IL-2, IL-4, IL-10, ECP, and TNF-α levels. 
The impact of probiotics on SCORAD indices is thought to 
be reduced by modification of immunogenicity of poten-
tial allergens. Probiotics are effective in the pathogenesis 
of AD through their effects such as restoring the mucosal 
barrier function in the intestines, degrading food antigens, 
regulating the intestinal microbial composition and acti-
vities, and stimulating the production of secretory IgA
23. 
They also block Th2 allergic response by stimulating Th1 
response
13,23-26. Probiotics regulate local and systemic 
immunity and thus alleviate the severity of clinical 
symptoms. 
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